MediLens Intelligence
Features

醫學研究趨勢

AI精選本週最具影響力的29個專科論文

最後更新: 2026年5月11日

心臟病學5

影響力 2

Day-of-the-week variation in ischemic stroke admissions in patients with atrial fibrillation.

發表日期: 2026-12-01

Annals of medicine

MediLens 收錄日: 2026-05-12

This study investigates the variation in ischemic stroke admissions among patients with atrial fibrillation (AF) based on the day of the week. Analyzing data from the nationwide FinACAF study, which included 13,781 patients with a mean age of 79.2 years, the results show significant differences i...

在PubMed上閱讀
影響力 3

Wrist-Measured Nighttime Home BP and Left Ventricular Hypertrophy: The WISDOM-HMOD Study.

發表日期: 2026-05-11

Hypertension (Dallas, Tex. : 1979)

MediLens 收錄日: 2026-05-12

The WISDOM-HMOD study evaluated the relationship between nighttime blood pressure measured by a wrist-type monitor and left ventricular hypertrophy in 1218 patients with hypertension or heart failure. Results showed an average nighttime systolic/diastolic BP of 110.5±13.0/63.5±8.8 mm Hg, with 70....

在PubMed上閱讀
影響力 3

Gene Therapy for Cardiomyopathy: Tools, Targets, and Trials.

發表日期: 2026-05-11

Circulation. Heart failure

MediLens 收錄日: 2026-05-12

This review addresses the significant advancements in cardiac gene therapy for cardiomyopathy, highlighting the transition of adeno-associated virus-mediated gene replacement into early-phase clinical trials. It notes improvements in biomarkers like NT-proBNP and discusses the challenges in deliv...

在PubMed上閱讀
影響力 3

Improved Cardiac Function and Glycemic Control in Elderly Diabetic Patients Through Structured Case Management After CABG.

發表日期: 2026-05-11

Medical science monitor : international medical journal of experimental and clinical research

MediLens 收錄日: 2026-05-12

This study evaluated the impact of a structured, multidisciplinary case management model on cardiac function and glycemic control in elderly patients with coronary heart disease and diabetes undergoing off-pump CABG. A total of 168 patients were randomized to receive either routine care or an enh...

在PubMed上閱讀
影響力 3

Finerenone and Empagliflozin in Type 2 Diabetes.

發表日期: 2026-05-11

Cardiology in review

MediLens 收錄日: 2026-05-12

This study highlights the critical role of sodium-glucose cotransporter 2 inhibitors and nonsteroidal mineralocorticoid receptor antagonists in reducing cardiovascular and kidney disease risks in patients with type 2 diabetes. Empagliflozin showed significant benefits in reducing cardiovascular m...

在PubMed上閱讀

獲取個人化每日摘要

全球醫生每天早上以AI文獻綜述開始新的一天。每早七點透過郵件發送。

開始7天免費試用